GILDD Stock Overview
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 2/6 |
Past Performance | 4/6 |
Financial Health | 4/6 |
Dividends | 4/6 |
Gilead Sciences, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$18.45 |
52 Week High | US$25.20 |
52 Week Low | US$16.70 |
Beta | 0.20 |
1 Month Change | -1.86% |
3 Month Change | -11.72% |
1 Year Change | -17.45% |
3 Year Change | 2.50% |
5 Year Change | n/a |
Change since IPO | -98.71% |
Recent News & Updates
Recent updates
Shareholder Returns
GILDD | AR Biotechs | AR Market | |
---|---|---|---|
7D | 8.8% | 0% | 0% |
1Y | -17.4% | 0% | 0% |
Return vs Industry: GILDD underperformed the AR Biotechs industry which returned -9% over the past year.
Return vs Market: GILDD underperformed the AR Market which returned 295.5% over the past year.
Price Volatility
GILDD volatility | |
---|---|
GILDD Average Weekly Movement | 8.2% |
Biotechs Industry Average Movement | 0% |
Market Average Movement | 0% |
10% most volatile stocks in AR Market | 0% |
10% least volatile stocks in AR Market | 0% |
Stable Share Price: GILDD's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine GILDD's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1987 | 18,000 | Dan O'Day | www.gilead.com |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.
Gilead Sciences, Inc. Fundamentals Summary
GILDD fundamental statistics | |
---|---|
Market cap | US$83.58b |
Earnings (TTM) | US$5.67b |
Revenue (TTM) | US$27.12b |
14.8x
P/E Ratio3.1x
P/S RatioIs GILDD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GILDD income statement (TTM) | |
---|---|
Revenue | US$27.12b |
Cost of Revenue | US$6.02b |
Gross Profit | US$21.10b |
Other Expenses | US$15.43b |
Earnings | US$5.67b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 25, 2024
Earnings per share (EPS) | 4.54 |
Gross Margin | 77.80% |
Net Profit Margin | 20.89% |
Debt/Equity Ratio | 109.8% |
How did GILDD perform over the long term?
See historical performance and comparison